At a glance
A short peptide explored in prostate-related experimental models.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses experimental prostatitis and tissue-marker findings. Animal changes in histology do not demonstrate symptom improvement or disease treatment in people.[1][2][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Prostamax.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (2 mL = 10 mg/mL)
| Phase / Week | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 5 units (0.05 mL) |
| Weeks 3–4 | 750 mcg (0.75 mg) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
| Weeks 9–12 (optional extension) | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
Route: Intramuscular (IM) injection once daily[1][2] Frequency: Inject once daily intramuscularly. Preclinical studies used daily IM administration for 15–60 days[1][2]. For administrations ≤10 units (≤0.10 mL), consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support prostate tissue health and function through bioregulatory peptide signaling[1][2].
- Schedule: Daily intramuscular injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 500 mcg–1 mg daily with gradual titration.
- Reconstitution: 2.0 mL per 20 mg vial (10 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 2 weeks.
Suggested daily titration approach.
- Start: 500 mcg (0.5 mg) daily; increase by ~250 mcg every 2 weeks as tolerated.
- Target: 1 mg daily by Weeks 5–8.
- Frequency: Once per day (intramuscular).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites among large muscle groups.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2 weeks.
Storage Instructions
Proper storage preserves peptide quality[7].
- Lyophilized (short‑term): Refrigerate at 4 °C (39.2 °F) in dry, dark conditions.
- Lyophilized (long‑term): Store at −20 °C (−4 °F) for extended stability.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~2 weeks and avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
Intramuscular administration guidance from clinical best‑practice resources[5][9].
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- For IM injection, use a 22–25 gauge, 1–1.5 inch needle inserted at 90° into a large muscle (deltoid, vastus lateralis, or gluteus)[5].
- Aspiration before IM injection is no longer routinely recommended for most sites[6].
- Inject slowly and steadily; wait briefly before withdrawing.
- Rotate sites systematically to avoid muscle irritation or fibrosis[8].
- Alternative (SC): If subcutaneous route is preferred, use a 23–25 gauge, 5/8 inch needle at 45° into fatty tissue[5].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Prostamax, 20 mg each):
- 8 weeks ≈ 2 vials (~40 mg total at ~0.7 mg/day average)
- 12 weeks ≈ 3 vials (~60 mg total)
- 16 weeks ≈ 4 vials (~80 mg total at ~1 mg/day maintenance)
-
Insulin Syringes (U‑100, 30‑ or 50‑unit recommended for precision):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- 12 weeks (3 vials): 6 mL → 1 × 10 mL bottle
- 16 weeks (4 vials): 8 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 05
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 06
Public health resource
CDC — Vaccine administration: During vaccination (aspiration guidance, aseptic technique) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
CDC — General best practices for immunization: injection technique and safety (opens in a new tab)www.cdc.gov
Back to overview ↑ - 10
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.